 |
|
Early promising results in malaria vaccine trial in Mali
January 23, 2008A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it. The trial was the first to test this vaccine candidate, which is designed to block the malaria parasite from entering human blood cells, in a malaria-endemic country. Based on these promising results, the research team is now conducting trials of this vaccine in 400 Malian children aged 1 to 6 years. Malaria is a leading killer in Africa and other developing countries, claiming more than 1 million lives each year, most of them children.
Lead investigator Mahamadou A. Thera M.D., MPH, and 16 other co-authors of the newly published study are based at the Malaria Research and Training Center at the University of Bamako, Mali. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, supported the trial and helps fund the Center. University of Maryland School of Medicine researcher Christopher Plowe, M.D., MPH, was the co-leader of the study.
The trial enrolled volunteers living in Bandiagara, a rural town in northeast Mali with a heavy burden of malaria. In this relatively dry region, almost no new infections occur during the driest month of the year, March, but people typically get up to 60 malaria-transmitting mosquito bites per month in August and September, when the rainy season peaks.
A total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control. Each volunteer received three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season. As expected, all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signaling that they had prior exposure to malaria parasites.
Those who received the candidate vaccine tolerated it very well and experienced a significant boost (up to a sixfold rise) in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.
NIH/National Institute of Allergy and Infectious Diseases
A total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control. Each volunteer received three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season. As expected, all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signaling that they had prior exposure to malaria parasites.
Those who received the candidate vaccine tolerated it very well and experienced a significant boost (up to a sixfold rise) in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.
NIH/National Institute of Allergy and Infectious Diseases
Malaria Vaccine Current Events and Malaria Vaccine News RSSPATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
UM School of Medicine researchers find extreme genetic variability in malaria parasite
Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world.
First genetically-engineered malaria vaccine to enter human trials
Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease.
Vaccine Blocks Malaria Transmission in Lab Experiments
Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine.
Promising trials of malaria vaccine lead to calls for Phase 3 development
Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported today in the New England Journal of Medicine (NEJM).
Researchers characterize potential protein targets for malaria vaccine
Researchers from Nijmegen and Leiden have now characterized a large number of parasite proteins that may prove useful in the development of a human malaria vaccine.
Case Western Reserve University School of Medicine researchers have evidence a vaccine against malaria will reduce infection and disease rates
Today, researchers at the Case Western Reserve University School of Medicine's Center for Global Health & Diseases published data potentially having a strong effect on the three billion people exposed to malaria every year.
New nanoparticle vaccine is more effective but less expensive
Good news for public health: Bioengineering researchers from the EPFL in Lausanne, Switzerland, have developed and patented a nanoparticle that can deliver vaccines more effectively, with fewer side effects, and at a fraction of the cost of current vaccine technologies.
Novel approach for rapid identification and development of malaria vaccines
Malaria is the world's most frequent parasitic disease, affecting more than 100 countries in the tropical zones, mostly in Africa, and 40% of the world population, with more than a million deaths per year.
Antibody-based therapies effective at controlling malaria
Passive immunization through the development of fully human antibodies specific to Plasmodium falciparum may be effective at controlling the disease, report researchers led by Dr. Richard S. McIntosh from the University of Nottingham in a paper published this week in the open-access journal PLoS Pathogens.
More Malaria Vaccine Current Events and Malaria Vaccine News Articles
 |
The Elusive Malaria Vaccine: Miracle or Mirage? by Irwin W. Sherman (Author) Chronicling a 100-year quest, this book tells the fascinating story of the hunt for the still-elusive malaria vaccine. Its clear, engaging style makes the book accessible to a general audience and brings to life all the drama of the hunt, celebrating the triumphs and documenting the failures. The author captures the controversies, missteps, wars of words, stolen ideas, and clashes of ego as researchers around the world compete to develop the first successful malaria vaccine. "The Elusive Malaria Vaccine: Miracle or Mirage?" is based on author Irwin W. Sherman's thorough investigation of the scientific literature as well as his first-hand interviews with today's pioneers in malaria vaccine research. As a result, the book offers remarkable insights into the keys to a successful malaria... |
 |
Molecular Immunological Considerations in Malaria Vaccine Development by Michael F. Good (Author), Allan J. Saul (Author) Some of the world's leading research scientists in the field have contributed to this new book on malaria vaccine development. The book examines various strategies being pursued against the different stages of the parasite (the sporozoite, asexual erythrocytic stages, and sexual stages). It describes vaccines that combat the parasite directly, vaccines aimed at preventing disease, vaccines based on attenuated parasites, and vaccines based on small, carefully defined synthetic peptides. The book provides a compendium of current approaches, lists of preferred antigens, and the results of vaccine trials to date. Molecular immunology involved with both the natural immune response to parasites and with the constraints on inducing immunity are emphasized throughout the book. Views on how... |
 |
Malaria: Malaria. Mosquito control, Malaria prophylaxis, Malaria vaccine, Antimalarial drug, History of malaria, Evolution, Natural selection by John McBrewster (Editor), Frederic P. Miller (Editor), Agnes F. Vandome (Editor) Malaria. Mosquito control, Malaria prophylaxis, Malaria vaccine, Antimalarial drug, History of malaria, Evolution, Natural selection, Diseases of poverty, Tropical disease, Sterile insect technique, Globalization and disease, Eradication of infectious diseases, The Global Fund to Fight AIDS, Tuberculosis and Malaria |
![The demand for a malaria vaccine: evidence from Ethiopia [An article from: Journal of Development Economics]](http://ecx.images-amazon.com/images/I/51F54J4ZBNL._SL160_.jpg) |
The demand for a malaria vaccine: evidence from Ethiopia [An article from: Journal of Development Economics] by M.L. Cropper (Author), M. Haile (Author), J. Lampietti (Author), C. Poulos (Author), W (Author) This digital document is a journal article from Journal of Development Economics, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: This study measures the monetary value households place on preventing malaria in Tigray, Ethiopia. We estimate a household demand function for a hypothetical malaria vaccine and compute the value of preventing malaria as the household's maximum willingness to pay to provide vaccines for all family members. This is contrasted with the traditional costs of illness (medical costs and lost productivity). Our results indicate that the value of preventing malaria with vaccines is about US$36 per household... |
|
Malaria Vaccine Development: A Multi-Immune Response Approach b | |
 |
Malaria: Waiting for the Vaccine by G. A. T. Targett (Editor) Malaria affects very large populations in tropical and sub-tropical areas of the world and the situation is now exacerbated by a growing resistance to drugs and insecticides by parasite and mosquito, respectively. Addresses the problem of public health management at the individual and community level, including the use and supply of drugs currently available as well as the economics of already strained health programs. The current status of vaccine development is assessed and recommendations are made for future research. |
|
Pnas (Proceeding of the National Academy of Sciences) February 16, 1999: Origin and Evolution of the ''Spanish'' Flu; Multistage Malaria Vaccine by National Academy of Sciences (Author) | |
 |
Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program by Committee on U.S. Military Malaria Vaccine Research - A Program Review (Author), Patricia M. Graves (Editor), Myron M. Levine (Editor) |
|
The Conference on Malaria in Africa - Proceedings : Practical Considerations on Malaria Vaccines and Clinical Trials by American Institute of Biological Sciences (Publisher) | |
|
Malaria: An entry from Thomson Gale's Gale Encyclopedia of Alternative Medicine by Mai Tran (Author) The term “Alternative Medicine” encompasses many forms, and elicits at least as many opinions. This authoritative, objective set is in tune with the subjects that matter to students and researchers, presenting four volumes of current, unbiased information on alternative and complementary medical practices. Covering all aspects of the subject—Therapies, Conditions/Diseases, Herbs/Plants and People—the “Gale Encyclopedia of Alternative Medicine” identifies 150 types of alternative medicine being practiced today, including reflexology, acupressure, acupuncture, chelation therapy, kinesiology, yoga, chiropractic, Feldenkrais, polarity therapy, detoxification, naturopathy, Chinese medicine, biofeedback, Ayurveda and osteopathy. For the practitioner or interested patient, there... |
| © 2009 BrightSurf.com |